DiaMedica Therapeutics Framtida tillväxt
Future kriterier kontrolleras 0/6
DiaMedica Therapeutics s intäkter förväntas minska med 8.2% per år medan dess årliga intäkter förväntas växa med 74.6% per år. EPS förväntas tillväxt med 2.4% per år.
Viktig information
-8.2%
Tillväxttakt i vinsten
2.43%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 25.2% |
| Intäkternas tillväxttakt | 74.6% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 08 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a KLK1 protein therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
DiaMedica Therapeutics (NASDAQ:DMAC) on Wednesday said the U.S. FDA had placed a clinical hold on its phase 2/3 trial evaluating its product candidate DM199 for the treatment of a type of stroke called acute ischemic stroke. The trial, called ReMEDy2, was put on hold as three serious cases of low blood pressure in stroke patients were reported after they received an injection of DM199. The company said it had paused patient enrollment, and believes the low blood pressure events were due to the use of a different intravenous bag in the ReMEDy2 trial from the one used in the prior ReMEDy1 trial. "...the company is confirming the differences in drug absorption in the IV bags used in the ReMEDy1 trial compared to the ReMEDy2 trial and plans to work with the FDA to modify the ReMEDy2 trial protocol to adjust the DM199 IV dosing to more closely match the dosing in the ReMEDy1 trial, taking into account these differences", DMAC said. DMAC said that no such low blood pressure issues were reported in the ReMEDy1 trial.We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a $3.5 billion U.S. market. They initiated a phase 2/3 pivotal trial. Their drug, DM199, is the first synthetic version of a naturally occurring protein, KLK1. Porcine and human-derived KLK1 have been used for 20+ years in Asia to treat stroke/kidney disease. A near-term Asian strategic partner could provide a $5-$20 million upfront payment with a potential of $50+ million in milestone payments for DM199 distribution rights. Insider buying of 110K+ shares in Q3-2021 is a very positive signal. The average price target from 5 Wall Street analysts is $22, or 5x the current price. A recent capital raise eliminates concern over any future dilution. No capital should be needed until mid-2023 after the pivotal stroke study results are released and the kidney indications.Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 5 | -76 | -67 | N/A | 3 |
| 12/31/2027 | N/A | -57 | -60 | -43 | 5 |
| 12/31/2026 | N/A | -46 | -46 | -40 | 5 |
| 3/31/2026 | N/A | -35 | -31 | -31 | N/A |
| 12/31/2025 | N/A | -33 | -29 | -29 | N/A |
| 9/30/2025 | N/A | -32 | -28 | -28 | N/A |
| 6/30/2025 | N/A | -30 | -26 | -26 | N/A |
| 3/31/2025 | N/A | -27 | -23 | -23 | N/A |
| 12/31/2024 | N/A | -24 | -22 | -22 | N/A |
| 9/30/2024 | N/A | -22 | -19 | -19 | N/A |
| 6/30/2024 | N/A | -20 | -20 | -20 | N/A |
| 3/31/2024 | N/A | -19 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -19 | -19 | -19 | N/A |
| 9/30/2023 | N/A | -18 | -18 | -18 | N/A |
| 6/30/2023 | N/A | -17 | -15 | -15 | N/A |
| 3/31/2023 | N/A | -15 | -13 | -13 | N/A |
| 12/31/2022 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2022 | N/A | -13 | -12 | -12 | N/A |
| 6/30/2022 | N/A | -14 | -12 | -12 | N/A |
| 3/31/2022 | N/A | -13 | -12 | -12 | N/A |
| 12/31/2021 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -13 | -12 | N/A |
| 6/30/2021 | N/A | -14 | -12 | -12 | N/A |
| 3/31/2021 | N/A | -13 | -11 | -11 | N/A |
| 12/31/2020 | N/A | -12 | -9 | -9 | N/A |
| 9/30/2020 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -10 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -10 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -11 | N/A | -9 | N/A |
| 9/30/2019 | N/A | -10 | N/A | -9 | N/A |
| 6/30/2019 | 1 | -9 | N/A | -10 | N/A |
| 3/31/2019 | 1 | -8 | N/A | -8 | N/A |
| 12/31/2018 | 1 | -6 | N/A | -6 | N/A |
| 9/30/2018 | 1 | -5 | N/A | -5 | N/A |
| 6/30/2018 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2018 | N/A | -4 | N/A | -4 | N/A |
| 12/31/2017 | N/A | -4 | N/A | -4 | N/A |
| 9/30/2017 | N/A | -4 | N/A | -4 | N/A |
| 6/30/2017 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2017 | N/A | -3 | N/A | -3 | N/A |
| 12/31/2016 | N/A | -2 | N/A | -3 | N/A |
| 9/30/2016 | N/A | -2 | N/A | -2 | N/A |
| 6/30/2016 | N/A | -2 | N/A | -2 | N/A |
| 3/31/2016 | N/A | -1 | N/A | -2 | N/A |
| 12/31/2015 | N/A | -2 | N/A | -2 | N/A |
| 9/30/2015 | N/A | -2 | N/A | -1 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: DMAC förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: DMAC förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: DMAC förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: DMAC förväntas inte ha några intäkter nästa år.
Hög tillväxtintäkter: DMAC förväntas inte ha några intäkter nästa år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om DMAC s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/25 04:43 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
DiaMedica Therapeutics Inc. bevakas av 13 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Kyle Bauser | Colliers Securities |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |